PPARGC1A

PPARGC1A
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesPPARGC1A, LEM6, PGC-1(alpha), PGC-1v, PGC1, PGC1A, PPARGC1, PGC-1alpha, PPARG coactivator 1 alpha, PGC-1α
External IDsOMIM: 604517; MGI: 1342774; HomoloGene: 7485; GeneCards: PPARGC1A; OMA:PPARGC1A - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_013261
NM_001330751
NM_001330752
NM_001330753

NM_008904

RefSeq (protein)
Location (UCSC)n/aChr 5: 51.61 – 51.73 Mb
PubMed search[2][3]
Wikidata
View/Edit HumanView/Edit Mouse

Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a protein that in humans is encoded by the PPARGC1A gene.[4] PPARGC1A is also known as human accelerated region 20 (HAR20). It may, therefore, have played a key role in differentiating humans from apes.[5]

PGC-1α is the master regulator of mitochondrial biogenesis.[6][7][8] PGC-1α is also the primary regulator of liver gluconeogenesis, inducing increased gene expression for gluconeogenesis.[9]

  1. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000029167Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ Esterbauer H, Oberkofler H, Krempler F, Patsch W (Feb 2000). "Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression". Genomics. 62 (1): 98–102. doi:10.1006/geno.1999.5977. PMID 10585775.
  5. ^ Pollard KS, Salama SR, Lambert N, Lambot MA, Coppens S, Pedersen JS, Katzman S, King B, Onodera C, Siepel A, Kern AD, Dehay C, Igel H, Ares M, Vanderhaeghen P, Haussler D (September 2006). "An RNA gene expressed during cortical development evolved rapidly in humans" (PDF). Nature. 443 (7108): 167–72. Bibcode:2006Natur.443..167P. doi:10.1038/nature05113. PMID 16915236. S2CID 18107797.
  6. ^ Valero T (2014). "Mitochondrial biogenesis: pharmacological approaches". Curr. Pharm. Des. 20 (35): 5507–9. doi:10.2174/138161282035140911142118. hdl:10454/13341. PMID 24606795. Mitochondrial biogenesis is therefore defined as the process via which cells increase their individual mitochondrial mass [3]. ... This work reviews different strategies to enhance mitochondrial bioenergetics in order to ameliorate the neurodegenerative process, with an emphasis on clinical trials reports that indicate their potential. Among them creatine, Coenzyme Q10 and mitochondrial targeted antioxidants/peptides are reported to have the most remarkable effects in clinical trials.
  7. ^ Sanchis-Gomar F, García-Giménez JL, Gómez-Cabrera MC, Pallardó FV (2014). "Mitochondrial biogenesis in health and disease. Molecular and therapeutic approaches". Curr. Pharm. Des. 20 (35): 5619–5633. doi:10.2174/1381612820666140306095106. PMID 24606801. Mitochondrial biogenesis (MB) is the essential mechanism by which cells control the number of mitochondria.
  8. ^ Dorn GW, Vega RB, Kelly DP (2015). "Mitochondrial biogenesis and dynamics in the developing and diseased heart". Genes Dev. 29 (19): 1981–91. doi:10.1101/gad.269894.115. PMC 4604339. PMID 26443844.
  9. ^ Klein MA, Denu JM (2020). "Biological and catalytic functions of sirtuin 6 as targets for small-molecule modulators". Journal of Biological Chemistry. 295 (32): 11021–11041. doi:10.1074/jbc.REV120.011438. PMC 7415977. PMID 32518153.

From Wikipedia, the free encyclopedia · View on Wikipedia

Developed by Tubidy